Edition:
Deutschland

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

164.04USD
16 Feb 2018
Change (% chg)

$-0.43 (-0.26%)
Prev Close
$164.47
Open
$164.35
Day's High
$165.71
Day's Low
$162.97
Volume
647,362
Avg. Vol
705,947
52-wk High
$256.78
52-wk Low
$156.00

AGN.N

Chart for AGN.N

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Buy/Sell

Sell Hold Buy
2.00 Mean rating from 22 analysts

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

UPDATE 2-Shares of Apricus tank after FDA declines to OK erectile dysfunction cream

* Co set to lose 76 pct of market value (Adds background on drug, analyst comment, updates share price)

BRIEF-Appaloosa Dissolves Share Stake In GM & Whirlpool, Ups Stake In Allergan

* APPALOOSA LP DISSOLVES SHARE STAKE IN GENERAL MOTORS CO - SEC FILING

BRIEF-Allergan Declares Q1 2018 Cash Dividend Of $0.72 Per Share

* ALLERGAN DECLARES FIRST QUARTER 2018 CASH DIVIDEND OF $0.72 PER ORDINARY SHARE AND PROVIDES ANNUAL GENERAL MEETING OF SHAREHOLDERS UPDATES Source text for Eikon: Further company coverage:

UPDATE 4-Teva warns on 2018 profit, may face migraine drug delays

* Teva expects to pay down $3.5 bln of debt in 2018 (Adds details about possible migraine drug delays)

BRIEF-Indivior Asserts New Patent Against ANDA-Filers

* U.S. UNIT FILED PATENT LAWSUITS AGAINST DR. REDDY'S, ACTAVIS, PAR, ALVOGEN AND TEVA FOR INFRINGEMENT OF UNITED STATES PATENT NO. 9,855,221

UPDATE 3-Allergan's profit beats; migraine drug succeeds in key study

Feb 6 Allergan Plc on Tuesday reported better-than-expected quarterly profit on robust demand for Botox, boosted its earnings forecast and announced positive data on one of the two migraine treatments it is developing.

BRIEF-Allergan Reports Q4 Non-GAAP Earnings Per Share $4.86

* ALLERGAN REPORTS SOLID FINISH TO 2017 WITH 12% INCREASE IN FOURTH QUARTER GAAP NET REVENUES TO $4.3 BILLION

Allergan posts quarterly profit; migraine treatment succeeds key study

Feb 6 Allergan Plc posted a quarterly profit, compared with a year-ago loss, due to recent changes in the U.S. tax laws, and the botox maker said its migraine treatment met the main goals in a late-stage study.

BRIEF-Allergan Announces Positive Phase 3 Results For Ubrogepant

* ALLERGAN ANNOUNCES POSITIVE TOP LINE PHASE 3 RESULTS FOR UBROGEPANT - AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.24%
Rohstoffe -0.32%
Industrie -0.21%
Konjunktur abhängige Waren & Dienstleistungen -0.18%
Konjunktur unabhängige Waren & Dienstleistungen -0.16%
Finanzindustrie -0.08%
Pharma -0.07%
Technologie -0.20%
Telekommunikation -0.05%